Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclophosphamide followed by taxane refers to a chemotherapy regimen commonly used in the treatment of breast cancer. The most typical formulation is the combination of cyclophosphamide (an alkylating agent) with a taxane such as docetaxel (Taxotere) or paclitaxel (Taxol). These drugs are administered sequentially or concurrently to destroy rapidly dividing cancer cells. Cyclophosphamide works by cross-linking DNA strands, thereby inhibiting cell division and leading to cell death. Taxanes stabilize microtubules and prevent their disassembly, which disrupts mitosis in cancer cells. This combination is often used as adjuvant therapy for early-stage HER2-negative breast cancer but may also be applied in other settings depending on patient characteristics[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclophosphamide + taxane.